NASDAQ: ICCCImmucell Corp Stock
$9.53-0.15 (-1.55%)
Updated Jun 15, 2026
ICCC Price
$9.53
Fair Value Price
N/A
Market Cap
$86.22M
52 Week Low
$4.52
52 Week High
$10.75
P/E
-136.14x
P/B
2.96x
P/S
1.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$29.93M
Earnings
-$545.40k
Gross Margin
42.6%
Operating Margin
-1.75%
Profit Margin
-1.8%
Debt to Equity
0.51
Operating Cash Flow
$4M
Beta
0.19
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ICCC Overview
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ICCC's potential to beat the market
- ICCC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ICCC
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important ICCC news, forecast changes, insider trades & much more!
ICCC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ICCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICCC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ICCC is good value based on its book value relative to its share price (2.96x), compared to the US Biotechnology industry average (4.89x)
P/B vs Industry Valuation
ICCC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ICCC due diligence checks available for Premium users.
Valuation
ICCC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-136.14x
Industry
16.41x
Market
14.3x
ICCC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.96x
Industry
4.89x
ICCC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ICCC's financial health
Profit margin
Revenue
$10.4M
Net Income
$1.9M
Profit Margin
18.7%
ICCC's Earnings (EBIT) of -$523.22k... subscribe to Premium to read more.
Interest Coverage Financials
ICCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$44.1M
Liabilities
$15.0M
Debt to equity
0.51
ICCC's short-term assets ($18.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICCC's short-term assets ($18.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICCC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ICCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.6M
Investing
-$167.2k
Financing
-$400.0k
ICCC's operating cash flow ($4.47M)... subscribe to Premium to read more.
Debt Coverage Financials
ICCC vs Biotech Stocks
Immucell Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.